Why Vaxart Stock Plunged 28.5% in December
Shares of Vaxart (NASDAQ: VXRT) tumbled 28.5% in December, according to data provided by S&P Global Market Intelligence, as investors continued to take stock of its oral COVID-19 vaccine.
The biotech rocketed to stratospheric heights earlier in the year on the promise that a coronavirus pill would be much better received by the public and the medical community. You wouldn't need to get a needle (or two), as is required with both Moderna's and the Pfizer-BioNTech vaccines, and being shelf stable, it doesn't require refrigeration, unlike the competing vaccines, which have a relatively short shelf life.
Image source: Getty Images.
Source Fool.com
